NanoString Technologies Announces Adoption of Prosigna Breast Cancer Assay by Leading US Clinical Laboratories and Cancer Centers

NanoString Technologies (NASDAQ: NSTG ) today announced nationwide availability of the Prosigna™ Breast Cancer Prognostic Gene Signature Assay beginning in the first quarter of 2014. Premier national diagnostic laboratories ARUP Laboratories, Laboratory Corporation of America® Holdings (LabCorp®) (LH), and Quest Diagnostics (DGX) have chosen to add the Prosigna Assay